Harvard Pilgrim Health CareCommercial · Prior Auth · Pharmacy · MA · Endocrinology, Family Medicine, Internal Medicine +1 moreHigh impact
Update on diabetic GLP-1 and GIP/GLP-1 drug coverage
Effective date
May 1, 2026
Identified
Jun 20, 2026
Summary
Harvard Pilgrim Health Care and Tufts Health Direct are removing automated step therapy for diabetic GLP-1 and GIP/GLP-1 medications (Ozempic, Mounjaro, Trulicity, etc.) effective May 1, 2026. All patients will now require prior authorization regardless of previous oral diabetes medication use, with coverage limited to type 2 diabetes patients who have tried or are currently taking oral hypoglycemic agents.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
01Before May 1, 2026: Billing team and providers must update workflows to require prior authorization for ALL diabetic GLP-1 and GIP/GLP-1 medications (Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity) for Harvard Pilgrim and Tufts Health Direct members.
02Update EMR templates to document type 2 diabetes diagnosis and oral hypoglycemic agent trial/failure.
03Train staff to submit requests through medical review process per Pharmacy Medical Necessity Guidelines for Incretin Mimetics.
04Claims will be denied without proper prior authorization.
Original notice
Update on diabetic GLP-1 and GIP/GLP-1 drug coverage
point32health.org · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.